Yael Webb is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations department. With a strong background in organic and medicinal chemistry, she has over 20 years of experience in patent prosecution and patent portfolio management. Her practice focuses on patent prosecution, due diligence, validity, patentability and freedom-to-operate analyses, and strategic planning of patent portfolios in the fields of chemistry, pharmaceuticals, and biotechnology.
Yael brings over two decades of drug development expertise in the biotech industry. She has a deep understanding of the entire life cycle of drug development and assists clients in realizing and protecting innovations from initial discovery and testing through all stages of clinical development. Previously, Yael was at ATON Pharma, where she was part of the team that led the discovery and development of the histone deacetylase inhibitor SAHA (Vorinostat), now marketed for the treatment of cutaneous T-cell lymphoma. More recently, she was with RyCarma Therapeutics, Inc., a biotech company developing a novel class of Ryanodine Receptor (RyR) channel modulators for the treatment of cardiovascular and skeletal muscle diseases. While in the pharmaceutical industry, Yael held a variety of roles in drug discovery, CMC, operations, intellectual property, and legal.
Yael completed her doctoral degree in chemistry at Columbia University and her postdoctoral training at Memorial Sloan Kettering Cancer Center. Her Ph.D. dissertation focused on the discovery and development of histone deacetylase inhibitors for the treatment of cancer. She is a co-author of several peer-reviewed publications and a co-inventor on two U.S. patents.
Yael Webb is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations department. With a strong background in organic and medicinal chemistry, she has over 20 years of experience in patent prosecution and patent portfolio management. Her practice focuses on patent prosecution, due diligence, validity, patentability and freedom-to-operate analyses, and strategic planning of patent portfolios in the fields of chemistry, pharmaceuticals, and biotechnology.
Yael brings over two decades of drug development expertise in the biotech industry. She has a deep understanding of the entire life cycle of drug development and assists clients in realizing and protecting innovations from initial discovery and testing through all stages of clinical development. Previously, Yael was at ATON Pharma, where she was part of the team that led the discovery and development of the histone deacetylase inhibitor SAHA (Vorinostat), now marketed for the treatment of cutaneous T-cell lymphoma. More recently, she was with RyCarma Therapeutics, Inc., a biotech company developing a novel class of Ryanodine Receptor (RyR) channel modulators for the treatment of cardiovascular and skeletal muscle diseases. While in the pharmaceutical industry, Yael held a variety of roles in drug discovery, CMC, operations, intellectual property, and legal.
Yael completed her doctoral degree in chemistry at Columbia University and her postdoctoral training at Memorial Sloan Kettering Cancer Center. Her Ph.D. dissertation focused on the discovery and development of histone deacetylase inhibitors for the treatment of cancer. She is a co-author of several peer-reviewed publications and a co-inventor on two U.S. patents.
- J.D., Fordham University School of Law, 2021Magna Cum Laude, Order of the Coif
- Ph.D., Chemistry, Columbia University, 1997
- B.Sc., Chemistry, Hebrew University of Jerusalem, 1992With Honors
- William Fulbright Scholar, United States-Israel Educational Foundation
- Fellow, Leukemia Society of America
- Pegram Award for meritorious achievement in chemical research, Columbia University
- Accounts of Chemical Research Graduate Award, Columbia University
- Malcolm Miller Distinguished Teaching Award, Columbia University
- State Bar of New York
- U.S. Patent and Trademark Office
- J.D., Fordham University School of Law, 2021Magna Cum Laude, Order of the Coif
- Ph.D., Chemistry, Columbia University, 1997
- B.Sc., Chemistry, Hebrew University of Jerusalem, 1992With Honors
- William Fulbright Scholar, United States-Israel Educational Foundation
- Fellow, Leukemia Society of America
- Pegram Award for meritorious achievement in chemical research, Columbia University
- Accounts of Chemical Research Graduate Award, Columbia University
- Malcolm Miller Distinguished Teaching Award, Columbia University
- State Bar of New York
- U.S. Patent and Trademark Office
Select Publications
- Co-author, “Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial.” 68 EClinicalMedicine 102433, February 2024
- Co-author, “Phase 1 “Open-Label Trial of Rycal S48168 (ARM210) for RYR1-Related Myopathies,” World Muscle Society (WMS) Congress, September 2022
- Co-author, “Safety, pharmacokinetics, and preliminary efficacy of Rycal S 48168 (ARM210) for RYR1-related myopathies: a phase one, open-label dose-escalation trial,” World Muscle Society (WMS) Congress, September 2021
- Co-author, “Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase,” 7(4) Clinical Cancer Research 962-970, 2001
- Co-author, “Inhibition of Protein Palmitoylation, raft localization and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids,” 275 Journal of Biological Chemistry 261-270, 2000
- Co-author, “Photoaffinity Labeling and Mass Spectrometry Identify Ribosomal Protein S3 as Potential Target for Hybrid Polar Cytodifferentiation Agents,” 274 Journal of Biological Chemistry 14280-14287, 1999
- Co-author, “A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases,” 95 Proceedings of the National Academy of Sciences of the United States of America 3003-3007, 1998
- Co-author, “Second generation hybrid polar compounds are potent inducers of transformed cell differentiation,” 93 Proceedings of the National Academy of Sciences of the United States of America 5705, 1996
- Co-author, “Further studies on the buffer catalyzed cleavage and isomerization of uridyl uridine. Medium and ionic strength effects on catalysis by morpholine, imidazole and acetate buffers help clarify the mechanism involved and their relationship to the mechanism used by the enzyme Ribonuclease and by a ribonuclease mimic,” 118 Journal of the American Chemical Society 6588, 1996
Select Publications
- Co-author, “Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial.” 68 EClinicalMedicine 102433, February 2024
- Co-author, “Phase 1 “Open-Label Trial of Rycal S48168 (ARM210) for RYR1-Related Myopathies,” World Muscle Society (WMS) Congress, September 2022
- Co-author, “Safety, pharmacokinetics, and preliminary efficacy of Rycal S 48168 (ARM210) for RYR1-related myopathies: a phase one, open-label dose-escalation trial,” World Muscle Society (WMS) Congress, September 2021
- Co-author, “Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase,” 7(4) Clinical Cancer Research 962-970, 2001
- Co-author, “Inhibition of Protein Palmitoylation, raft localization and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids,” 275 Journal of Biological Chemistry 261-270, 2000
- Co-author, “Photoaffinity Labeling and Mass Spectrometry Identify Ribosomal Protein S3 as Potential Target for Hybrid Polar Cytodifferentiation Agents,” 274 Journal of Biological Chemistry 14280-14287, 1999
- Co-author, “A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases,” 95 Proceedings of the National Academy of Sciences of the United States of America 3003-3007, 1998
- Co-author, “Second generation hybrid polar compounds are potent inducers of transformed cell differentiation,” 93 Proceedings of the National Academy of Sciences of the United States of America 5705, 1996
- Co-author, “Further studies on the buffer catalyzed cleavage and isomerization of uridyl uridine. Medium and ionic strength effects on catalysis by morpholine, imidazole and acetate buffers help clarify the mechanism involved and their relationship to the mechanism used by the enzyme Ribonuclease and by a ribonuclease mimic,” 118 Journal of the American Chemical Society 6588, 1996
Biological Sciences and Biotechnology
- Biochemical assays
- Biochemistry
- Bioconjugation
- Cancer biology
- Cancer therapeutics
- Cell therapy
Therapeutics and Drug Discovery
- Antimicrobial agents
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Pharmacodynamics
- Pharmacokinetics
- Pharmacology
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Catalysis
- Chemical synthesis
- Chemistry
- Chemoenzymatic synthesis
- Organic chemistry
- Organometallics
- Peptidomimetics
- Polymers
- Polymorph
- Process chemistry
Miscellaneous
- Cancer
- Food science
- Formulations
- PharmD
Biological Sciences and Biotechnology
- Biochemical assays
- Biochemistry
- Bioconjugation
- Cancer biology
- Cancer therapeutics
- Cell therapy
Therapeutics and Drug Discovery
- Antimicrobial agents
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Pharmacodynamics
- Pharmacokinetics
- Pharmacology
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Catalysis
- Chemical synthesis
- Chemistry
- Chemoenzymatic synthesis
- Organic chemistry
- Organometallics
- Peptidomimetics
- Polymers
- Polymorph
- Process chemistry
Miscellaneous
- Cancer
- Food science
- Formulations
- PharmD
- Privacy Policy
- Terms of Use
- Accessibility